Following the presentation of the phase Ib LIO-1 Dr Nicole Concin provides an overview of the design of the phase II LIO-1 trial and the rationale behind lucitanib plus nivolumab as a potential therapy for solid tumours.The poster ‘LIO-1: A Phase 2 Study of Lucitanib + Nivolumab in Patients (pts) With Gynaecological Tumours’ was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020, and can be found here. The phase Ib LIO-1 poster can be found here.
- What is the rationale behind using a combination of a tyrosine kinase inhibitor plus a monoclonal antibody targeting PD1? (0:23)
- What is the mechanism of action of lucitanib plus nivolumab? (2:52)
- What do we already know about this combination and how will this inform the phase II LIO-1 trial? (3:37)
- What are the aims and design of the phase II LIO-1 trial? (6:14)
- What are the future directions for the phase II LIO-1 trial? (9:08)
Speaker Disclosure: Nicole Concin has been an advisor for AstraZeneca, Mersana, and Seattle Genetics; has received travel/accommodation expenses from Amgen, Genmab, and Roche; and has received personal fees and travel expenses from Medscape
Support: Interview and filming supported by Touch Medical Media Ltd. The LIO-1 trial was sponsored by Clovis Oncology, Inc.
Filmed in coverage of the Virtual 2020 ESMO Congress.
PD1 = programmed cell death protein 1.
Share this Video
Related Videos In Gynecological Oncology
Nicole Concin, ESMO 2020 – The Launch of the Phase II LIO-1 Trial Investigating Lucitanib plus Nivolumab in Advanced Metastatic Solid Tumours
Following the presentation of the phase Ib LIO-1 Dr Nicole Concin provides an overview of the design of the phase II LIO-1 trial and the rationale behind lucitanib plus nivolumab as a potential therapy for solid tumours.The poster ‘LIO-1: A Phase 2 Study of Lucitanib + Nivolumab in Patients (pts) With Gynaecological Tumours’ was presented […]
Linda Mileshkin, ESMO 2019 – Phase III OUTBACK trial in cervical cancer
We joined Linda Mileshkin (Peter MacCallum Cancer Centre) following her presentation at ESMO 2019 to discuss the disparities of starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial. Questions 1. Could you tell us a little about the OUTBACK trial and its findings? (0:06) 2. What was […]
Jonathan A Ledermann – Maintenance Treatment for Recurrent Ovarian Carcinoma
Jonathan A Ledermann (UCL Cancer Institute and University College London Hospitals, London, UK) speaks to us around the topic of the review article he recently co-authored entitled: Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors, which is freely available to access here. Questions 1. For patients with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!